Announcements Trials
Browse Landscape

Phase

Phase 2/3 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Plasma cell 1Genitourinary 1Gastrointestinal 1

Conditions

Colorectal Neoplasms 4606Pancreatic Neoplasms 2845Carcinoma, Hepatocellular 2480Stomach Neoplasms 2330Colonic Neoplasms 1791Rectal Neoplasms 1720Esophageal Neoplasms 1376Liver Neoplasms 921Neoplasms 915Breast Neoplasms 839Neoplasm Metastasis 765Carcinoma, Non-Small-Cell Lung 707Cholangiocarcinoma 587Lung Neoplasms 557Ovarian Neoplasms 535Esophageal Squamous Cell Carcinoma 514Gastrointestinal Neoplasms 495Melanoma 381Prostatic Neoplasms 373Biliary Tract Neoplasms 373Head and Neck Neoplasms 303Uterine Cervical Neoplasms 288Carcinoma, Renal Cell 284Adenocarcinoma Of Esophagus 273Squamous Cell Carcinoma of Head and Neck 264Sarcoma 264Gastrointestinal Stromal Tumors 252Endometrial Neoplasms 235Urinary Bladder Neoplasms 226Gallbladder Neoplasms 225

Interventions

Pharmaceutical Preparations 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Interventional × Familial Mediterranean Fever × Gastrointestinal × Clear all
NCT00035334 2006-02-14

Study of the Safety and Efficacy of NC-503 in Secondary (AA) Amyloidosis

Bellus Health Inc. - a GSK company

Phase 2/3 Completed
150 enrolled
GastrointestinalGenitourinaryPlasma cell

Amyloidosis, Arthritis, Rheumatoid, Gastrointestinal Diseases, Kidney Diseases, Neoplasm Metastasis, Nephrotic Syndrome, Familial Mediterranean Fever

Data powered by HemOnc (CC BY 4.0) Colophon âš¡